Use this button to switch between dark and light mode.

FDA-Based Failure-to-Report Claims State Law Survey

March 11, 2025 (1 min read)

This state law survey summarizes the legal landscape across the 50 U.S. states and the District of Columbia surrounding Food, Drug, and Cosmetic Act (FDCA)-based failure-to-warn claims predicated on violations of the reporting requirements of the FDCA. It identifies states that recognize failure-to-report claims as a cause of action and provides valuable insight into the case law of states that do not recognize failure to report claims as a cause of action.

Read now »


Related Content

  • FDA Warning Letters Tracker
    Monitor trends in enforcement activity with this curated tracker of Warning Letters affecting FDA-regulated companies and products.

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.

  • The Practical Guidance Journal 2025 Edition One features guidance on what attorneys need to know about deepfake technology, a look ahead at AI risk management, an artificial intelligence checklist, and a review of cautions and key AI legal issues in DEI and employment discrimination.
  • Browse the Practical Guidance Author Center to see the 2000+ leading attorney authors contributing to our 26 practice areas. Interested in becoming a Practical Guidance author? Click here for details. Practical Guidance is committed to amplifying diverse voices of attorneys across all differences, including gender and race.

PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB

Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+

Review these newsletters to preview Practical Guidance coverage of recent legal developments in your practice area.

Practical Guidance customers who are logged in will be directed to the full linked content.

Not yet a Practical Guidance Subscriber? Sign up for a FREE seven-day trial here to access summaries of the linked content and gain access to full coverage during your trial.